Quanterix Corp
A maker of ultra-sensitive blood tests and tissue-imaging tools for biology research and diagnostics. Its Simoa platform detects single protein molecules in blood, powering tests like LucentAD Complete for Alzheimer's disease, while its PhenoCycler spatial biology systems map proteins inside intact tissue. Founded in 2007 by scientist David Walt, whose lab invented the single-molecule array technology, the company began life as Digital Genomics before renaming itself Quanterix. Simoa is short for "single molecule array," and the firm grew further by acquiring spatial-biology pioneer Akoya Biosciences in 2025.
Granted 18.5K · Bought 417.0K
Granted 206.3K · Bought 64.9K
Granted 24.6K
Granted 10.4K
Granted 35.4K · Bought 113.3K
Granted 70.1K
Granted 70.1K
Granted 21.1K
Granted 33.8K
Granted 54.8K
Granted 43.6K
Granted 42.8K
Granted 6.7K
Granted 83.5K · Bought 4.2K
Granted 2.9K
Granted 4.9K · Sold 6.5K
Granted 60.4K
Bought 3.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Walt David RDirector · 11 transactions | +30% | 1.87M | 18.5K | 417.0K | — |
| Toloue MasoudPresident & CEO, Director · 58 transactions | +74.7% | 507.3K | 206.3K | 64.9K | — |
| Meister Paul MDirector · 11 transactions | +8.5% | 313.3K | 24.6K | — | — |
| Madaus Martin DDirector · 2 transactions | +3.7% | 291.5Kas of Jan 2025 | 10.4K | — | — |
| Donnelly William PExecutive Chair, Director · 15 transactions | +1770.9% | 154.1K | 35.4K | 113.3K | — |
| Doyle Michael ACFO and Treasurer · 2 transactions | -0.3% | 88.3Kas of Sep 2023 | — | — | — |
| Hampton Malcolm GarretDirector · 2 transactions | — | 70.1K | 70.1K | — | — |
| Sachs Alan BruceDirector · 2 transactions | — | 70.1K | 70.1K | — | — |
| Hlavinka Sarah E.Director · 10 transactions | +54.3% | 60.1Kas of Jul 2025 | 21.1K | — | — |
| Flynn KarenDirector · 3 transactions | +153.8% | 57.2K | 33.8K | — | — |
| Lai Goldman MylaDirector · 5 transactions | — | 54.8K | 54.8K | — | — |
| Magovcevic-Liebisch IvanaDirector · 3 transactions | — | 43.6K | 43.6K | — | — |
| Elliott Jeffrey ThomasDirector · 3 transactions | — | 42.8K | 42.8K | — | — |
| Miller Michael FrancisChief Technology Officer · 48 transactions | — | 33.9K | 6.7K | — | — |
| Sriram VandanaChief Financial Officer · 51 transactions | +150.3% | 31.6K | 83.5K | 4.2K | — |
| Blaser Brian JDirector · 1 transaction | +18.3% | 19.0Kas of Jan 2024 | 2.9K | — | — |
| Olson Laurie JDirector · 8 transactions | -10.2% | 13.7Kas of May 2024 | 4.9K | — | 6.5K |
| Mendel ScottDirector · 6 transactions | — | 12.5K | 60.4K | — | — |
| Meadows BenjaminChief Commercial Officer · 1 transaction | — | 3.5K | — | 3.5K | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: +596.4K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.